Search - tctmd.com

Displaying 461 - 480 of 952

Sort: Relevancy | Date

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

News Industry News

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

October 31, 2013

News Industry News

New Study Evaluates Outcomes of Providing Access to Platelet Function Testing in a Clinical Setting

October 31, 2013

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Industry News

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

News Industry News

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

October 30, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

Presenter: Masato Nakamura

October 29, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

Presentation

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

Presenter: Deepak Bhatt

October 29, 2013

News Industry News

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

October 29, 2013

News Conference News TCT 2013

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

October 29, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

News Conference News TCT 2013

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

October 28, 2013

Presentation TCT 2013

LAA Closure in Patients Who Need Dual Antiplatelet Therapy: Rationale and Results

Presenter: Zoltan Turi

October 27, 2013

Advertisement

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Studies Find Differing Benefits of Platelet, Genotype Testing

OPTIMIZE: 3-Month DAPT Safe with ZES

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

New Study Evaluates Outcomes of Providing Access to Platelet Function Testing in a Clinical Setting

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

Innovation in Intervention: Perspectives from Industry

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

Cre8, BioFreedom Polymer-Free DES Show Promise

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

LAA Closure in Patients Who Need Dual Antiplatelet Therapy: Rationale and Results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content